- Final report of initial preclinical study confirms Cymerus™ MSCs have significant beneficial effects on all three key components of asthma: airway hyper-responsiveness, inflammation and airway remodelling
- Additional preclinical study expected to pave the way for a potential clinical trial
Melbourne, Australia; 2 March 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has signed an agreement with the Monash Lung Biology Network, a consortia involving researchers from the Monash Biomedicine Discovery Institute and Department of Pharmacology at Monash University, Melbourne, to conduct a further preclinical study to support the use of CymerusTM mesenchymal stem cells (MSCs) for the treatment of asthma. [Read more…]